Key facts
- This page summarizes Phillip Samayoa's Form 4 filing for Generation Bio Co. (GBIO).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 14 Jan 2025, 16:05.
Phillip Samayoa - 10 Jan 2025 Form 4 Insider Report for Generation Bio Co. (GBIO)
- Reporting relationship
- CHIEF SCIENTIFIC OFFICER
- Issuer ticker
- GBIO
- Reported as of
- 10 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Jan 2025, 16:05:12 UTC
- Prior SEC filing
- 17 Oct 2024
- Next SEC filing
- 17 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Shawna-Gay White, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Phillip Samayoa filed Form 4 for Generation Bio Co. (GBIO) on 14 Jan 2025.
Change
- Previous filing in this sequence was filed on 17 Oct 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GBIO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 126,960
- Date
- 10 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GBIO
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +251,030
- Change %
- Price
- $0.000000
- Shares after
- 251,030
- Date
- 10 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 251,030
- Exercise price
- $0.9260
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Includes 4,863 shares acquired under the company's employee stock purchase plan since October 15, 2024.
Footnote F2
The option to purchase 251,030 shares was granted on January 10, 2025. The shares underlying the option vest over four years, with 25% of the shares vesting on January 10, 2026 and the remaining shares vesting in equal quarterly installments thereafter.